A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus.
A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus.
复制标题
靶向S1蛋白的二价重组疫苗诱导针对SARS-CoV-2变异体和野生型病毒的中和抗体。
作者：
He C;Yang J;He X;Hong W;Lei H;Chen Z;Shen G;Yang L;Li J;Wang Z;Song X;Wang W;Lu G;Wei X
大流行中严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 的新变种要求紧急开发 2019 年冠状病毒病 (COVID-19) 通用疫苗，该疫苗对野生型 SARS-CoV-2 和突变株均有效。在本研究中，我们用AS03佐剂和SARS-CoV-2 S1亚基（S1-WT）和S1变体（K417N、E484K、N501Y和D614G）亚基（S1-Mut）的重组蛋白配制了蛋白亚单位疫苗，并免疫表达人血管紧张素转换酶2（hACE2）的转基因小鼠。在小鼠免疫后测量了 S1 蛋白特异性抗体的产生以及对 SARS-CoV-2 和 B.1.351 变体的中和能力。结果显示，与野生型 SARS-CoV-2 相比，S1-Mut 抗原在抑制 B.1.351 变体中的受体结合域和 ACE2 结合方面更有效。此外，二价疫苗的开发表现出针对野生型和 B.1.351 变体以及其他变体的理想中和特性。我们的研究结果可能为开发针对 S1 蛋白的二价重组疫苗提供理论依据，该疫苗可以诱导针对 SARS-CoV-2 变体和野生型病毒的中和抗体，并且对于探索二价重组疫苗未来的潜在临床应用可能具有重要意义。由 SARS-CoV-2 的 S1 亚基和 S1 变体（K417N、E484K、N501Y 和 D614G）亚基组成的二价重组疫苗可以诱导针对 SARS-CoV-2 变体和野生型病毒的中和抗体。
The emerging variants of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) in pandemic call for the urgent development of universal corona virus disease 2019 (COVID‐19) vaccines which could be effective for both wild‐type SARS‐CoV‐2 and mutant strains. In the current study, we formulated protein subunit vaccines with AS03 adjuvant and recombinant proteins of S1 subunit of SARS‐CoV‐2 (S1‐WT) and S1 variant (K417N, E484K, N501Y, and D614G) subunit (S1‐Mut), and immunized transgenic mice that express human angiotensin‐converting enzyme 2 (hACE2). The S1 protein‐specific antibody production and the neutralization capability for SARS‐CoV‐2 and B.1.351 variant were measured after immunization in mice. The results revealed that the S1‐Mut antigens were more effective in inhibiting the receptor‐binding domain and ACE2 binding in B.1.351 variant than in wild‐type SARS‐CoV‐2. Furthermore, the development of a bivalent vaccine exhibited the ideal neutralization properties against wild‐type and B.1.351 variant, as well as other variants. Our findings may provide a rationale for the development of a bivalent recombinant vaccine targeting the S1 protein that can induce the neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus and may be of importance to explore the potential clinical use of bivalent recombinant vaccine in the future. The bivalent recombinant vaccine composed of S1 subunit of SARS‐CoV‐2 and S1 variant (K417N, E484K, N501Y, and D614G) subunit could induce the neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus.
登录
查看更多内容
DOI：
10.1126/science.abc4730
发表时间：
2020-09-25
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Gu H;Chen Q;Yang G;He L;Fan H;Deng YQ;Wang Y;Teng Y;Zhao Z;Cui Y;Li Y;Li XF;Li J;Zhang NN;Yang X;Chen S;Guo Y;Zhao G;Wang X;Luo DY;Wang H;Yang X;Li Y;Han G;He Y;Zhou X;Geng S;Sheng X;Jiang S;Sun S;Qin CF;Zhou Y
通讯作者：
Zhou Y
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S
DOI：
10.1056/nejmoa2102214
发表时间：
2021-05-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Madhi SA;Baillie V;Cutland CL;Voysey M;Koen AL;Fairlie L;Padayachee SD;Dheda K;Barnabas SL;Bhorat QE;Briner C;Kwatra G;Ahmed K;Aley P;Bhikha S;Bhiman JN;Bhorat AE;du Plessis J;Esmail A;Groenewald M;Horne E;Hwa SH;Jose A;Lambe T;Laubscher M;Malahleha M;Masenya M;Masilela M;McKenzie S;Molapo K;Moultrie A;Oelofse S;Patel F;Pillay S;Rhead S;Rodel H;Rossouw L;Taoushanis C;Tegally H;Thombrayil A;van Eck S;Wibmer CK;Durham NM;Kelly EJ;Villafana TL;Gilbert S;Pollard AJ;de Oliveira T;Moore PL;Sigal A;Izu A;NGS-SA Group;Wits-VIDA COVID Group
通讯作者：
Wits-VIDA COVID Group
影响因子：
30.3
作者：
Plante JA;Mitchell BM;Plante KS;Debbink K;Weaver SC;Menachery VD
通讯作者：
Menachery VD
影响因子：
82.9
作者：
Wibmer, Constantinos Kurt;Ayres, Frances;Moore, Penny L.
通讯作者：
Moore, Penny L.